HC Wainwright Has Bullish Estimate for ZNTL Q2 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Zentalis Pharmaceuticals in a note issued to investors on Thursday, May 15th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.43) for the quarter, up from their previous estimate of ($0.52). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.57) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.67).

ZNTL has been the topic of a number of other research reports. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Finally, UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Trading Down 5.5%

Shares of NASDAQ:ZNTL traded down $0.07 during mid-day trading on Monday, reaching $1.21. The stock had a trading volume of 747,105 shares, compared to its average volume of 1,548,941. The business's 50 day moving average price is $1.41 and its 200 day moving average price is $2.30. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $13.00. The company has a market cap of $87.06 million, a P/E ratio of -0.49 and a beta of 1.81.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now owns 281,192 shares of the company's stock, valued at $393,668.80. The trade was a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ZNTL. Barclays PLC lifted its stake in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after purchasing an additional 11,748 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Zentalis Pharmaceuticals by 22.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company's stock valued at $1,507,000 after buying an additional 91,152 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $76,000. SG Americas Securities LLC lifted its stake in shares of Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock worth $171,000 after acquiring an additional 30,240 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Zentalis Pharmaceuticals by 169.2% during the 4th quarter. Russell Investments Group Ltd. now owns 60,021 shares of the company's stock worth $182,000 after acquiring an additional 37,726 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.